Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device
Liquid biopsy is a noninvasive method for detecting and quantifying circulating tumor cells (CTCs). Thanks to ScreenCell technology, this study aims to evaluate the evolution of the number of CTCs during breast cancer follow-up. The identification and characterization of CTCs would make it possible to obtain information on the stage and molecular characteristics of cancer during follow-up
Conditions studied
Breast Cancer, Metastatic, Breast Cancer Invasive, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
About this study
Liquid biopsy is a noninvasive method for detecting and quantifying circulating tumor cells (CTCs). Thanks to ScreenCell technology, this study aims to evaluate the evolution of the number of CTCs during breast cancer follow-up. The identification and characterization of CTCs would make it possible to obtain information on the stage and molecular characteristics of cancer during follow-up
Interventions
- Device: The DM/DIV ScreenCell is the experimental product studied during this research — The product is not used directly on the subject, but on a blood sample taken from the participant.
Primary outcomes
- Evolution of the kinetics of CTC during treatment (From enrollement to the end of follow up at 9 months)
Eligibility information
Study locations
- CMC Ambroise Paré Hartmann, Neuilly-sur-Seine, 92200 France
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.